4 May 2016 - PHARMAC is seeking feedback on two proposals to list two new treatments for hepatitis C.

The proposals are as a result of two separate provisional agreements one with Gilead Sciences (NZ) Ltd and another with AbbVie Ltd. In summary, the proposals would result in, from 1 July 2016:

• Ledipasvir with sofosbuvir (Harvoni) being funded in the community and DHB hospitals for the treatment of hepatitis C for patients with severe liver disease.
• Paritaprevir with ritonavir and ombitasvir copackaged with dasabuvir (Viekira Pak) and paritaprevir with ritonavir and ombitasvir copackaged with dasabuvir and ribavirin (Viekira Pak-RBV) being funded in the community and DHB hospitals for the treatment of hepatitis C.

On August 10 2015, PHARMAC released a Request for Information (RFI) on hepatitis C treatments and received feedback from suppliers, clinicians, advocacy groups and patients. Feedback to the RFI helped to inform our analysis and development of these proposals.

For more details, go to: http://www.pharmac.govt.nz/news/consultation-2016-05-04-hepatitis-c-treatments/